Clinical Trial Update: Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 Years [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating immunogenicity of the HPV vaccine Cervarix in healthy women aged 26 years and older; results posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Infection

Drugs mentioned

• Cervarix (human papillomavirus vaccine, bivalent)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Papillomavirus | Phase 3 | Status: COMPLETED | Results posted: 2010-07-30